These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy. Sinadinos A; Young CN; Al-Khalidi R; Teti A; Kalinski P; Mohamad S; Floriot L; Henry T; Tozzi G; Jiang T; Wurtz O; Lefebvre A; Shugay M; Tong J; Vaudry D; Arkle S; doRego JC; Górecki DC PLoS Med; 2015 Oct; 12(10):e1001888. PubMed ID: 26461208 [TBL] [Abstract][Full Text] [Related]
4. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Banks GB; Chamberlain JS Curr Top Dev Biol; 2008; 84():431-53. PubMed ID: 19186250 [TBL] [Abstract][Full Text] [Related]
10. Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy. Porter JD; Merriam AP; Leahy P; Gong B; Feuerman J; Cheng G; Khanna S Hum Mol Genet; 2004 Feb; 13(3):257-69. PubMed ID: 14681298 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic strategies for Duchenne and Becker dystrophies. Voisin V; de la Porte S Int Rev Cytol; 2004; 240():1-30. PubMed ID: 15548414 [TBL] [Abstract][Full Text] [Related]
12. Effect of calpain and proteasome inhibition on Ca2+-dependent proteolysis and muscle histopathology in the mdx mouse. Briguet A; Erb M; Courdier-Fruh I; Barzaghi P; Santos G; Herzner H; Lescop C; Siendt H; Henneboehle M; Weyermann P; Magyar JP; Dubach-Powell J; Metz G; Meier T FASEB J; 2008 Dec; 22(12):4190-200. PubMed ID: 18728218 [TBL] [Abstract][Full Text] [Related]
14. [Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation]. Zhang C; Feng HY; Huang SL; Fang JP; Xiao LL; Yao XL; Chen C; Ye X; Zeng Y; Lu XL; Wen JM; Zhang WX; Li Z; Feng SW; Xu HG; Huang K; Zhou DH; Chen W; Xie YM; Xi J; Zhang M; Li Y; Liu Y Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Aug; 22(4):399-405. PubMed ID: 16086277 [TBL] [Abstract][Full Text] [Related]
15. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Deconinck N; Dan B Pediatr Neurol; 2007 Jan; 36(1):1-7. PubMed ID: 17162189 [TBL] [Abstract][Full Text] [Related]
16. Diagnosis and cell-based therapy for Duchenne muscular dystrophy in humans, mice, and zebrafish. Kunkel LM; Bachrach E; Bennett RR; Guyon J; Steffen L J Hum Genet; 2006; 51(5):397-406. PubMed ID: 16583129 [TBL] [Abstract][Full Text] [Related]
17. Exercise increases utrophin protein expression in the mdx mouse model of Duchenne muscular dystrophy. Gordon BS; Lowe DA; Kostek MC Muscle Nerve; 2014 Jun; 49(6):915-8. PubMed ID: 24375286 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy. Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862 [TBL] [Abstract][Full Text] [Related]
19. Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins. Tidball JG; Wehling-Henricks M Mol Genet Metab; 2004 Aug; 82(4):312-20. PubMed ID: 15308129 [TBL] [Abstract][Full Text] [Related]
20. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Wang B; Li J; Xiao X Proc Natl Acad Sci U S A; 2000 Dec; 97(25):13714-9. PubMed ID: 11095710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]